S&P 500   3,960.68 (-0.07%)
DOW   33,706.55 (-0.22%)
QQQ   284.04 (+0.07%)
AAPL   144.29 (+1.15%)
MSFT   247.03 (-0.15%)
META   116.77 (+1.25%)
GOOGL   93.67 (-0.04%)
AMZN   89.36 (-1.10%)
TSLA   179.98 (+3.77%)
NVDA   172.71 (+0.59%)
NIO   12.85 (-4.18%)
BABA   92.15 (-2.15%)
AMD   69.57 (-1.28%)
T   19.21 (+0.47%)
MU   55.49 (+0.53%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.86 (-3.46%)
PYPL   74.18 (-0.05%)
PFE   51.91 (+0.25%)
NFLX   325.29 (+4.84%)
S&P 500   3,960.68 (-0.07%)
DOW   33,706.55 (-0.22%)
QQQ   284.04 (+0.07%)
AAPL   144.29 (+1.15%)
MSFT   247.03 (-0.15%)
META   116.77 (+1.25%)
GOOGL   93.67 (-0.04%)
AMZN   89.36 (-1.10%)
TSLA   179.98 (+3.77%)
NVDA   172.71 (+0.59%)
NIO   12.85 (-4.18%)
BABA   92.15 (-2.15%)
AMD   69.57 (-1.28%)
T   19.21 (+0.47%)
MU   55.49 (+0.53%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.86 (-3.46%)
PYPL   74.18 (-0.05%)
PFE   51.91 (+0.25%)
NFLX   325.29 (+4.84%)
S&P 500   3,960.68 (-0.07%)
DOW   33,706.55 (-0.22%)
QQQ   284.04 (+0.07%)
AAPL   144.29 (+1.15%)
MSFT   247.03 (-0.15%)
META   116.77 (+1.25%)
GOOGL   93.67 (-0.04%)
AMZN   89.36 (-1.10%)
TSLA   179.98 (+3.77%)
NVDA   172.71 (+0.59%)
NIO   12.85 (-4.18%)
BABA   92.15 (-2.15%)
AMD   69.57 (-1.28%)
T   19.21 (+0.47%)
MU   55.49 (+0.53%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.86 (-3.46%)
PYPL   74.18 (-0.05%)
PFE   51.91 (+0.25%)
NFLX   325.29 (+4.84%)
S&P 500   3,960.68 (-0.07%)
DOW   33,706.55 (-0.22%)
QQQ   284.04 (+0.07%)
AAPL   144.29 (+1.15%)
MSFT   247.03 (-0.15%)
META   116.77 (+1.25%)
GOOGL   93.67 (-0.04%)
AMZN   89.36 (-1.10%)
TSLA   179.98 (+3.77%)
NVDA   172.71 (+0.59%)
NIO   12.85 (-4.18%)
BABA   92.15 (-2.15%)
AMD   69.57 (-1.28%)
T   19.21 (+0.47%)
MU   55.49 (+0.53%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.86 (-3.46%)
PYPL   74.18 (-0.05%)
PFE   51.91 (+0.25%)
NFLX   325.29 (+4.84%)
NASDAQ:INVA

Innoviva - INVA Stock Forecast, Price & News

$13.47
-0.17 (-1.25%)
(As of 12/9/2022 01:33 PM ET)
Add
Compare
Today's Range
$13.35
$13.68
50-Day Range
$11.61
$13.78
52-Week Range
$11.56
$20.71
Volume
17,669 shs
Average Volume
592,506 shs
Market Capitalization
$939.94 million
P/E Ratio
4.22
Dividend Yield
N/A
Price Target
$14.00

Innoviva MarketRank™ Forecast

Analyst Rating
Hold
1.50 Rating Score
Upside/​Downside
4.2% Upside
$14.00 Price Target
Short Interest
Bearish
14.94% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.33
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
-59.37%
From $3.47 to $1.41 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.94 out of 5 stars

Medical Sector

1001st out of 1,022 stocks

Pharmaceutical Preparations Industry

487th out of 499 stocks

INVA stock logo

About Innoviva (NASDAQ:INVA) Stock

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

INVA Stock News Headlines

Innoviva (INVA) Q3 Earnings and Revenues Lag Estimates
Innoviva Completes Acquisition of La Jolla...
See More Headlines
Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

INVA Company Calendar

Last Earnings
11/09/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/08/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INVA
Previous Symbol
NASDAQ:THRX
CUSIP
88338T10
Employees
5
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$14.00
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+3.9%
Consensus Rating
Hold
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

Net Income
$265.85 million
Pretax Margin
109.35%

Debt

Sales & Book Value

Annual Sales
$391.87 million
Cash Flow
$4.73 per share
Book Value
$7.56 per share

Miscellaneous

Free Float
69,162,000
Market Cap
$939.94 million
Optionable
Optionable
Beta
0.57

Social Links


Key Executives

  • Mr. Pavel Raifeld C.F.A. (Age 38)
    Chief Exec. Officer
    Comp: $690.81k
  • Ms. Marianne Zhen CPAMs. Marianne Zhen CPA (Age 53)
    Chief Accounting Officer & Sec.
    Comp: $462.18k













INVA Stock - Frequently Asked Questions

Should I buy or sell Innoviva stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" INVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INVA, but not buy additional shares or sell existing shares.
View INVA analyst ratings
or view top-rated stocks.

What is Innoviva's stock price forecast for 2023?

2 Wall Street research analysts have issued 1 year target prices for Innoviva's stock. Their INVA share price forecasts range from $14.00 to $14.00. On average, they expect the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 2.6% from the stock's current price.
View analysts price targets for INVA
or view top-rated stocks among Wall Street analysts.

How have INVA shares performed in 2022?

Innoviva's stock was trading at $17.25 at the beginning of the year. Since then, INVA stock has decreased by 20.9% and is now trading at $13.64.
View the best growth stocks for 2022 here
.

When is Innoviva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023.
View our INVA earnings forecast
.

How were Innoviva's earnings last quarter?

Innoviva, Inc. (NASDAQ:INVA) posted its quarterly earnings data on Wednesday, November, 9th. The biotechnology company reported $0.60 earnings per share for the quarter, missing analysts' consensus estimates of $2.75 by $2.15. The biotechnology company had revenue of $67.26 million for the quarter, compared to the consensus estimate of $361.45 million. Innoviva had a trailing twelve-month return on equity of 23.89% and a net margin of 78.39%.

What other stocks do shareholders of Innoviva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Who are Innoviva's major shareholders?

Innoviva's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.61%), Vanguard Group Inc. (10.04%), Renaissance Technologies LLC (6.12%), Dimensional Fund Advisors LP (4.21%), LSV Asset Management (3.96%) and State Street Corp (3.54%). Insiders that own company stock include George Bickerstaff, Innoviva, Inc, Marianne Zhen and Plc Glaxosmithkline.
View institutional ownership trends
.

How do I buy shares of Innoviva?

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Innoviva's stock price today?

One share of INVA stock can currently be purchased for approximately $13.64.

How much money does Innoviva make?

Innoviva (NASDAQ:INVA) has a market capitalization of $951.80 million and generates $391.87 million in revenue each year. The biotechnology company earns $265.85 million in net income (profit) each year or $3.19 on an earnings per share basis.

How can I contact Innoviva?

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The official website for the company is www.inva.com. The biotechnology company can be reached via phone at (650) 238-9600, via email at investor.relations@inva.com, or via fax at 650-827-8690.

This page (NASDAQ:INVA) was last updated on 12/9/2022 by MarketBeat.com Staff